1. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype
- Author
-
Maria Di Bari, María Elena Sales, Alejandro Javier Español, Yamila Sanchez, Ada Maria Tata, Agustina Reina Salem, and Ilaria Cristofaro
- Subjects
0301 basic medicine ,Vascular Endothelial Growth Factor A ,Atropine ,Cancer Treatment ,Triple Negative Breast Neoplasms ,THERAPY ,Biochemistry ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,METRONOMIC ,Cell Movement ,breast cancer ,muscarinic receptors ,paclitaxel ,Angiogenesis ,Muscarinic acetylcholine receptor ,Antineoplastic Combined Chemotherapy Protocols ,Breast Tumors ,Medicine and Health Sciences ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Epidermal growth factor receptor ,RNA, Small Interfering ,Receptor ,Multidisciplinary ,biology ,Neovascularization, Pathologic ,Chemistry ,Pharmaceutics ,Drugs ,Muscarinic acetylcholine receptor M2 ,Esters ,purl.org/becyt/ford/3.1 [https] ,Small interfering RNA ,CANCER ,Neoplasm Proteins ,ErbB Receptors ,Gene Expression Regulation, Neoplastic ,Nucleic acids ,Paclitaxel ,Oncology ,030220 oncology & carcinogenesis ,Physical Sciences ,Medicine ,purl.org/becyt/ford/3 [https] ,Female ,medicine.drug ,Research Article ,Agonist ,Carbachol ,Drug Administration ,medicine.drug_class ,Cell Survival ,Science ,Arecoline ,Down-Regulation ,Cholinergic Agonists ,BREAST ,03 medical and health sciences ,Alkaloids ,Drug Therapy ,Cell Line, Tumor ,Breast Cancer ,medicine ,Genetics ,Animals ,Humans ,Non-coding RNA ,Cell Proliferation ,Pharmacology ,Receptor, Muscarinic M2 ,Biology and life sciences ,Chemical Compounds ,Cancers and Neoplasms ,Xenograft Model Antitumor Assays ,Gene regulation ,030104 developmental biology ,Tumor progression ,Administration, Metronomic ,Cancer research ,biology.protein ,RNA ,Gene expression - Abstract
Triple negative tumors are more aggressive than other breast cancer subtypes and there is a lack of specific therapeutic targets on them. Since muscarinic receptors have been linked to tumor progression, we investigated the effect of metronomic therapy employing a traditional anti-cancer drug, paclitaxel plus muscarinic agonists at low doses on this type of tumor. We observed that MDA-MB231 tumor cells express muscarinic receptors, while they are absent in the non-tumorigenic MCF-10A cell line, which was used as control. The addition of carbachol or arecaidine propargyl ester, a non-selective or a selective subtype 2 muscarinic receptor agonist respectively, plus paclitaxel reduces cell viability involving a downregulation in the expression of ATP “binding cassette” G2 drug transporter and epidermal growth factor receptor. We also detected an inhibition of tumor cell migration and anti-angiogenic effects produced by those drug combinations in vitro and in vivo (in NUDE mice) respectively. Our findings provide substantial evidence about subtype 2 muscarinic receptors as therapeutic targets for the treatment of triple negative tumors. Fil: Español, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Salem, Agustina Reina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Di Bari, María. Università degli Studi di Roma "La Sapienza"; Italia Fil: Cristofaro, Ilaria. Università degli Studi di Roma "La Sapienza"; Italia Fil: Sanchez, Yamila. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina Fil: Tata, Ada Maria. Università degli Studi di Roma "La Sapienza"; Italia Fil: Sales, María Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina
- Published
- 2020